Shelley
Lv13
20 积分
2022-05-13 加入
-
Enhancing in situ cancer vaccines using delivery technologies
5分钟前
待确认
-
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
58分钟前
已完结
-
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
22小时前
已完结
-
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
1天前
已完结
-
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
2天前
已完结
-
PARP Inhibitors for Breast Cancer Treatment
2天前
已完结
-
Exploring and comparing adverse events between PARP inhibitors
8天前
已完结
-
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
9天前
已完结
-
Efficacy and safety of serplulimab (an anti-PD-1 antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy (074)
11天前
已完结
-
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601
13天前
已完结